Do analysts rate QLGN or YDKG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Yueda Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, QLGN or YDKG?

Qualigen Therapeutics has higher earnings, but lower revenue than Yueda Digital. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Yueda Digital $28.15M 0.16 -$28.06M N/A N/A

Is QLGN or YDKG more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Yueda Digital N/A N/A N/A

Do analysts rate QLGN or IFBD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Infobird 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, QLGN or IFBD?

Qualigen Therapeutics has higher earnings, but lower revenue than Infobird. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Infobird $8.71M 0.60 -$57.19M N/A N/A

Is QLGN or IFBD more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Infobird N/A N/A N/A

Do analysts rate CSAI or QLGN?

Cloudastructure currently has a consensus target price of $45.00, indicating a potential upside of 1,008.37%. Given Cloudastructure's stronger consensus rating and higher possible upside, analysts plainly believe Cloudastructure is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cloudastructure 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend QLGN or RIME?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Algorhythm 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend WCT or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wellchange 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, WCT or QLGN?

Qualigen Therapeutics has lower revenue, but higher earnings than Wellchange. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Wellchange $1.35M 3.07 -$7.32M N/A N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is WCT or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Wellchange N/A N/A N/A Qualigen Therapeutics N/A N/A -202.16%

Qualigen Therapeutics (QLGN) Competitors

$0.90 +0.16 (+21.13%)

As of 09/11/2026

Compare

QLGN vs. YDKG, IFBD, CSAI, RIME, and WCT

Should you buy Qualigen Therapeutics stock or one of its competitors? Qualigen Therapeutics's main competitors and comparable companies include Yueda Digital (YDKG), Infobird (IFBD), Cloudastructure (CSAI), Algorhythm (RIME), and Wellchange (WCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Qualigen Therapeutics compare to Yueda Digital?

Qualigen Therapeutics (NASDAQ:QLGN) and Yueda Digital (NASDAQ:YDKG) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Yueda Digital has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Yueda Digital shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 7.5% of Yueda Digital shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Yueda Digital	N/A	N/A	N/A

In the previous week, Yueda Digital had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Yueda Digital and 0 mentions for Qualigen Therapeutics. Yueda Digital's average media sentiment score of 1.43 beat Qualigen Therapeutics' score of 0.00 indicating that Yueda Digital is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Yueda Digital	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Yueda Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has higher earnings, but lower revenue than Yueda Digital.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Yueda Digital	$28.15M	0.16	-$28.06M	N/A	N/A

Summary

Yueda Digital beats Qualigen Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Infobird?

Qualigen Therapeutics (NASDAQ:QLGN) and Infobird (NASDAQ:IFBD) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Infobird had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Infobird and 0 mentions for Qualigen Therapeutics. Infobird's average media sentiment score of 1.89 beat Qualigen Therapeutics' score of 0.00 indicating that Infobird is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Infobird	Very Positive

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of Infobird shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 35.5% of Infobird shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Infobird has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Qualigen Therapeutics has higher earnings, but lower revenue than Infobird.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Infobird	$8.71M	0.60	-$57.19M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Infobird	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Infobird	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Infobird beats Qualigen Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cloudastructure?

Cloudastructure (NASDAQ:CSAI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Qualigen Therapeutics has a net margin of 0.00% compared to Cloudastructure's net margin of -145.25%. Qualigen Therapeutics' return on equity of 0.00% beat Cloudastructure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cloudastructure	-145.25%	-167.05%	-103.30%
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, Cloudastructure had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Cloudastructure and 0 mentions for Qualigen Therapeutics. Cloudastructure's average media sentiment score of 0.43 beat Qualigen Therapeutics' score of 0.00 indicating that Cloudastructure is being referred to more favorably in the media.

Company	Overall Sentiment
Cloudastructure	Neutral
Qualigen Therapeutics	Neutral

Qualigen Therapeutics has lower revenue, but higher earnings than Cloudastructure. Cloudastructure is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cloudastructure	$5.07M	0.70	-$8.46M	-$14.33	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 21.8% of Cloudastructure shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cloudastructure has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Cloudastructure currently has a consensus target price of $45.00, indicating a potential upside of 1,008.37%. Given Cloudastructure's stronger consensus rating and higher possible upside, analysts plainly believe Cloudastructure is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cloudastructure	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cloudastructure beats Qualigen Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Algorhythm?

Qualigen Therapeutics (NASDAQ:QLGN) and Algorhythm (NASDAQ:RIME) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Qualigen Therapeutics has a net margin of 0.00% compared to Algorhythm's net margin of -176.39%. Qualigen Therapeutics' return on equity of 0.00% beat Algorhythm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Algorhythm	-176.39%	-1,310.33%	-101.29%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.9% of Algorhythm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Algorhythm had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Algorhythm and 0 mentions for Qualigen Therapeutics. Algorhythm's average media sentiment score of 1.87 beat Qualigen Therapeutics' score of 0.00 indicating that Algorhythm is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Algorhythm	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Algorhythm	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Qualigen Therapeutics has higher earnings, but lower revenue than Algorhythm. Algorhythm is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Algorhythm	$4.39M	0.93	-$15.87M	-$1.49	N/A

Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Algorhythm has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Summary

Qualigen Therapeutics beats Algorhythm on 7 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Wellchange?

Wellchange (NASDAQ:WCT) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Wellchange	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, Wellchange had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Wellchange and 0 mentions for Qualigen Therapeutics. Wellchange's average media sentiment score of 0.30 beat Qualigen Therapeutics' score of 0.00 indicating that Wellchange is being referred to more favorably in the media.

Company	Overall Sentiment
Wellchange	Neutral
Qualigen Therapeutics	Neutral

Wellchange has a beta of 2.97, meaning that its share price is 197% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wellchange	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has lower revenue, but higher earnings than Wellchange.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wellchange	$1.35M	3.07	-$7.32M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Wellchange beats Qualigen Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QLGN vs. The Competition

Export

Metric	Qualigen Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$1.52M	$15.42B	$29.99B	$12.84B
Dividend Yield	N/A	3.44%	2.74%	11.71%
P/E Ratio	-0.12	138.70	76.73	25.35
Price / Sales	N/A	1,291.66	592.46	90.72
Price / Cash	N/A	41.74	46.59	34.96
Price / Book	-0.22	8.28	7.72	6.21
Net Income	-$6.26M	$434.47M	$704.35M	$358.54M
7 Day Performance	26.39%	-2.15%	-1.16%	-2.39%
1 Month Performance	29.75%	-1.46%	-3.96%	-3.39%
1 Year Performance	-57.30%	-0.20%	180.49%	8.81%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QLGN Qualigen Therapeutics	N/A	$0.90 +21.1%	N/A	-57.3%	$1.52M	N/A	N/A	50	Gap Up
YDKG Yueda Digital	1.0135 of 5 stars	$0.93 +2.2%	N/A	N/A	$5.04M	$28.15M	N/A	70	Short Interest Decrease
IFBD Infobird	1.2752 of 5 stars	$0.92 +2.7%	N/A	-17.7%	$4.90M	$8.71M	N/A	390	Gap Up
CSAI Cloudastructure	2.3872 of 5 stars	$5.05 -1.6%	$45.00 +791.1%	-91.0%	$4.45M	$5.07M	N/A	20	Short Interest Increase Gap Up
RIME Algorhythm	0.7281 of 5 stars	$0.25 +3.5%	N/A	-88.5%	$4.12M	$4.39M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. YDKG, IFBD, CSAI, RIME, and WCT

How does Qualigen Therapeutics compare to Yueda Digital?

Summary

How does Qualigen Therapeutics compare to Infobird?

Summary

How does Qualigen Therapeutics compare to Cloudastructure?

Summary

How does Qualigen Therapeutics compare to Algorhythm?

Summary

How does Qualigen Therapeutics compare to Wellchange?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. YDKG, IFBD, CSAI, RIME, and WCT

How does Qualigen Therapeutics compare to Yueda Digital?

Which has more risk and volatility, QLGN or YDKG?

Do insiders and institutionals have more ownership in QLGN or YDKG?

Is QLGN or YDKG more profitable?

Does the media favor QLGN or YDKG?

Do analysts rate QLGN or YDKG?

Which has higher valuation & earnings, QLGN or YDKG?

Summary

How does Qualigen Therapeutics compare to Infobird?

Does the media favor QLGN or IFBD?

Do insiders & institutionals have more ownership in QLGN or IFBD?

Which has more risk & volatility, QLGN or IFBD?

Which has preferable earnings and valuation, QLGN or IFBD?

Is QLGN or IFBD more profitable?

Do analysts rate QLGN or IFBD?

Summary

How does Qualigen Therapeutics compare to Cloudastructure?

Is CSAI or QLGN more profitable?

Does the media refer more to CSAI or QLGN?

Which has stronger valuation and earnings, CSAI or QLGN?

Do institutionals and insiders have more ownership in CSAI or QLGN?

Which has more volatility & risk, CSAI or QLGN?

Do analysts rate CSAI or QLGN?

Summary

How does Qualigen Therapeutics compare to Algorhythm?

Is QLGN or RIME more profitable?

Do institutionals & insiders believe in QLGN or RIME?

Does the media prefer QLGN or RIME?

Do analysts recommend QLGN or RIME?

Which has stronger earnings & valuation, QLGN or RIME?

Which has more volatility and risk, QLGN or RIME?

Summary

How does Qualigen Therapeutics compare to Wellchange?

Is WCT or QLGN more profitable?

Does the media refer more to WCT or QLGN?

Which has more risk & volatility, WCT or QLGN?

Do analysts recommend WCT or QLGN?

Which has preferable earnings & valuation, WCT or QLGN?

Do institutionals and insiders hold more shares of WCT or QLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools